Formulation and In-vitro characterization of Acyclovir floating matrix tablets: A factorial design study

Journal of Applied Pharmaceutical Science

Volumn 3, Issue 5, 2013, Pages 65-74

  Shahi, Sadhana ^a   Sonawane, Ashok ^a   Vanamore, Suhas ^a   Zadbuke, Nityanand Subhash ^a  

^a GOVERNMENT COLLEGE OF PHARMACY   (India)

Author keywords

Acyclovir; Floating matrix tablet; HPMC K15M CR; Polyox WSR 303

Indexed keywords

EID: 84880638434     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: 10.7324/JAPS.2013.3513     Document Type: Article

References (31)

1. Davis S.S., Formulation strategies for absorption windows. Drug Discovery Today. 2005; 10:249-257.
2. Singh B.N., Kim K.H. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Rel. 2000; 63:235-259.
3. Reddy L.H., Murthy R.S. Floating dosage systems in drug delivery. Crit Rev Ther Drug Carrier Syst. 2002; 19: 53-585.
4. Seth P.R., Tossounian J. The hydrodynamically balanced system, a novel drug delivery system for oral use. Drug Dev Ind Pharm. 1984; 10:313-339.
5. Harrigan R.M. Drug delivery device for preventing contact of undissolved drug with the stomach lining. US Patent 4055178. 1977.
6. Whitehead L., Fell J.T., Collett J.H. Development of a gastroretentive dosage form. Eur J Pharm Sci 1996; 4(Suppl):S182.
7. Kawashima Y., Niwa T., Takeuchi H., Hino T., Itoh Y. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci. 1992; 81:135-140.
8. Fiddian A.P., Brigden D., Yeo J.M., Hickmott E.A. Acyclovir: an update of the clinical applications of this antiherpes agent. Antiviral Research. 1984; 4:99-117.
9. Glaxo Wellcome Inc. International final study report, 1 Jun 1984 through 30 Apr 1999. Acyclovir Pregnancy Registry. 1999.
10. American Society of Hospital Pharmacists (AHFS). AHFS Drug Information, Bethesda, MD, 2004:765-775.
11. Tao Y., Lu Y., Sun Y., Gu B., Lu W., Pan J. Development of mucoadhesive microspheres of Acyclovir with enhanced bioavailability. Int J Pharm 2009; 378:30-36.
12. Lewis L.D., Fowle A.S., Bitiner S.B., Bye A., Isaacs P.E. Human gastrointestinal absorption of Acyclovir from tablet duodenal infusion and sipped solution. Br J Clin Pharmac.1986; 21:459-462.
13. Kagan L., Hoffman A. Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model. Eur J Pharm Biopharm. 2008; 69:238-246.
14. Groning R., Berntgen M., Georgarakis M. Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. Eur J Pharm Biopharm. 1998; 46:285-291.
15. Tavakoli N., Varshosaz J., Dorkoosh F., Motaghi S., Tamaddon L. Development and evaluation of a monolithic floating drug delivery system for Acyclovir. Chem Pharm Bull. 2012; 60:172-177.
16. Dias R.J., Sakhare S.S., Mali K.K. Design and development of mucoadhesive Acyclovir tablet. Iranian J Pharm Res. 2009; 8(4):231-239.
17. Dhaliwal S., Jain S., Singh H.P., Tiwary A.K. Mucoadhesive microspheres for gastroretentive delivery of Acyclovir: in-vitro and in-vivo evaluation. AAPS. 2008; 10(2) DOI: 10.1208/s12248-008-9039-2.
18. Nur A.O., Zhang J.S. Captopril floating and/or bioadhesive tablets: design and release kinetics. Drug Dev Ind Pharm.2000; 26(9):965- 969.
19. Gusler G. Optimal polymer mixtures for gastric retentive tablets. US Patent 6723340.2004.
20. Maggi L., Segale L., Torre M.L., Machiste E.O., Conte U. Dissolution behaviour of hydrophilic matrix tablets containing two different polyethylene oxides (PEOs) for the controlled release of a watersoluble drug: Dimensionality study. Biomaterials. 2002; 23:1113-1119.
21. Monajjemzadeh F., Hassanzadeh D., Valizadeh H., Mohammad R., Robertson T.A., Roberts M.S. Compatibility studies of Acyclovir and lactose in physical mixtures and commercial tablets. Eur J Pharm Biopharm. 2009; 73:404-413.
22. Higuchi T. Mechanism of sustained action medication. J. Pharm. Sci. 1963; 52:1145-1149.
23. Korsmeyer R.W., Gurny R., Docler E., Buri P., Peppas N.A., Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15:25-35.
24. International Conference on Harmonisation. ICH Q1A (R2): Stability testing of new drug substances and products (http://www.ich.org/LOB/media/MEDIA419.pdf).
25. Garg R., Gupta G.D. Preparation and evaluation of gastroretentive floating tablets of Silymarin. Chem Pharm Bull. 2009; 57(6):545-549.
26. Gambhire M.N., Ambade K.W., Kurmi S.D., Kadam V.J., Jadhav K.R. Development and in-vitro evaluation of an oral floating matrix tablet formulation of diltiazem hydrochloride. AAPS Pharm Sci Tech. 2007; 8(3):E1-E9.
27. United States Pharmacopeia 27 and National Formulary 22, Asian Edition, United States Pharmacopeial Convention, Inc., Rockville, 2004.
28. Siepmann J., Peppas N.A. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Del Rev. 2001; 48:139-157.
29. Kulkarni A., Bhatia M. Development and evaluation of regioselective bilayer floating tablets of atenolol and lovastatin for biphasic release profile. Iran J Pharm Res. 2009; 8(1):15-25.
30. Peppas N.A. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985; 60:110-111.
31. Shah N., Zhang G., Apelian V., Zeng F., Infeld M.H., Malick A.W. Prediction of drug release from hydroxypropyl methylcellulose (HPMC) matrices: effect of polymer concentration. Pharm Res. 1993; 10:1693-1695.